CNN Story Features DBV Technologies’ VIASKIN® Skin Patch for the Desensitization of Peanut Allergy

The Peanut-Allergy “Patch”

“Our VIASKIN® technology offers a whole new paradigm for the treatment of food allergies. We are proud that our Peanut patch is attracting such worldwide media coverage, which reinforces our determination to ultimately bring to market a safe and efficacious treatment option for peanut allergy.”

Pierre-Henri Benhamou, M.D., CEO.

PARIS--()--DBV Technologies, an emerging biotechnology company, is pleased to report that an independently produced story featuring its VIASKIN® skin patch for the desensitization of peanut allergy has appeared on the worldwide news network CNN: The Peanut-Allergy “Patch.”

About VIASKIN® Technology

When the VIASKIN patch containing a specific allergen is applied to the skin of a patient with an IgE-mediated allergy — such as peanuts or milk — the allergens are deposited locally on the skin and are captured specifically by the skin’s immuno-competent cells. This triggers the modulations of the immune responses. The epicutaneous exposure is non-invasive: the skin naturally prevents the allergen from entering the bloodstream and thereby dramatically reduces the risk of inducing anaphylaxis. The VIASKIN patch, the “Allergy Patch”, is designed to be easily and painlessly applied by healthcare professionals and also by the patient or his/her parents at home, which facilitates compliance with the treatment.

About VIASKIN® Peanut Immunotherapy

A phase 1b clinical study of VIASKIN Peanut sponsored by DBV Technologies is underway at five centers in the U.S. — Duke University Medical Center, National Jewish Medical Research Center, Arkansas Children’s Hospital, CRI Worldwide, and Aspen Clinical Research. VIASKIN Peanut’s development is also supported by the NIH-funded Consortium of Food Allergy Research (CoFAR) and other opinion leaders in allergy in the United States.

About DBV Technologies

DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies. Allergen-specific immunotherapy is the only strategy that treats the underlying cause of an allergic disorder. DBV’s proprietary epicutaneous patch technology — VIASKIN® — involves maintaining an allergen on the skin of an allergic subject for repeated and prolonged periods in order to obtain clinical desensitization.

NOTE: VIASKIN® Peanut is only for investigational use at the moment in the USA and in Europe.

Contacts

Ronald Trahan Associates, Inc.
Ronald Trahan, 508-359-4005, ext. 108
APR

Release Summary

"Peanut patch" is attracting worldwide media coverage for DBV Technologies' VIASKIN® technology.

Sharing

Contacts

Ronald Trahan Associates, Inc.
Ronald Trahan, 508-359-4005, ext. 108
APR